Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Peripheral neuropathy is a common adverse effect of neurotoxic chemotherapy. In a randomized, double-blind clinical trial, an investigational hand therapy was not more effective at preventing ...

1 The Third Clinical Medical School, Zhejiang Chinese Medicine University, Hangzhou, China 2 Institute of International Education of Zhejiang Chinese Medical University, Hangzhou, China Background: ...

Figures in parentheses refer to results during the corresponding period of the previous yearThe Group's sales amounted to 64.8 (61.2) MSEK for the third quarter of the year.The Group's net result tota ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Additionally, Artelo’s pipeline includes a FABP5 inhibitor, ART26.12, which has received clearance for a Phase 1 study and is aimed at conditions like chemotherapy-induced peripheral neuropathy.

Scientists have designed a groundbreaking painkiller that activates solely at chronic pain sites, offering targeted, ...

Artelo Biosciences ( (ARTL) ) has released its Q3 earnings. Here is a breakdown of the information Artelo Biosciences presented to its ...